secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alkermes plc. (ALKS)
CIK:        0001520262
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0000950170-25-061441
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alkermes Q1 2025 revenue $306.5M, GAAP EPS $0.13; reaffirms 2025 guidance
-------------------------------------------------------------------------

- Total revenues $306.5M, down from $350.4M in Q1 2024; GAAP net income $22.5M ($0.13 diluted EPS).
- Proprietary net sales $244.5M (+5% YoY); LYBALVI grew 23% to $70.0M, VIVITROL $101.0M, ARISTADA $73.5M.
- Cash and investments $916.2M, up from $824.8M at Dec. 31, 2024.
- ALKS 2680 phase 2 Vibrance-1 enrollment complete; topline data expected early Q3 2025.
- Company reiterates full-year 2025 financial expectations as communicated Feb. 12, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1520262/000095017025061441/0000950170-25-061441-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1520262/000095017025061441/alks-20250501.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-061441

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer